Shots: The P-ll study involves assessing of ATYR1923 (1.0 & 3.0 mg/kg) vs PBO in 32 hospitalized COVID-19 patients in the ratio of (1:1:1) with severe respiratory complications who do not require mechanical ventilation in the US and Puerto Rico Result: the study met its 1EPs of safety, demonstrating that ATYR1923 (single dose, IV) was […]Read More
Shots: The P-IV HER-MES study involves assessing Aimovig (erenumab 70mg and 140mg) vs topiramate in 777 patients in a ratio (1:1) with episodic or chronic migraine (≥4 migraine days/month) prior not treated with migraine prevention treatment or previously failed up to three prophylactic migraine treatments The study met its 1EPs & 2EPs and had superior […]Read More
Shots: The P-IIIa Dupixent Eosinophilic Esophagitis study involves assessing Dupixent (N=42) (300mg weekly) v/s PBO (N=39) in 81 patients aged 12 years and older with eosinophilic esophagitis (EoE). In addition, enrolling patients for P-IIIb for extended active treatment period to continue in 28wks The P-II study results: met its co-1EPs and 2EPs in DSQ baseline […]Read More
Shots: The P-III EDITION JUNIOR study involves assessing Toujeo vs Gla-100 (insulin glargine 100 Units/mL) in 463 children and adolescents aged 6-17yrs. with T1D for at least 1yr. and with HbA1c b/w 7.5% and 11.0% at screening The P-III EDITION JUNIOR study resulted in meeting its 1EPs i.e, reduction in average blood sugar over 6 […]Read More
Shots: The P-III MINISTONE-2 involves assessing of Xofluza vs oseltamivir in children with influenza infection & showing influenza symptoms aged 1 to <12yrs., resulted in meeting its 1EPs i.e, patients with AEs up to day 29 (46.1% vs 53.4%) and reduction in length of time that the flu virus continued to be released from the […]Read More
Shots: The P-III FLAURA study involves assessing of Tagrisso (80mg, qd) vs EGFR-TKIs (erlotinib, 50mg, qd /gefitinib, 250mg, qd) in 556 patients with LA/metastatic EGFRm NSCLC across 29 countries In Jul’2017, the P-III FLAURA study met its 1EPs of improvement in PFS and the updated results demonstrated improvement in OS with safety & tolerability profile […]Read More
Shots: Roche is presenting data that includes results assessing Tecentriq + nab-paclitaxel in Breast Cancer (P-III), Alecensa in lung cancer and Tecentriq in lung (P-III) and liver cancers(P-I) Additionally, presenting Entrectinib’s (RXDX-101) positive results from P-II STARTRK-2, P-I STARTRK-1 and P-I ALKA trials for NTRK gene fusion-positive solid tumors and also received BT and PRIME […]Read More
Shots: The P-I BE study involves assessing of PK limitations i.e. Cmax, AUC for Xspray’s leading product HyNap-Dasa formulated vs Sprycel (Dasatinib) The P-I study (N=16) with healthy candidates administrating single dose of each product, demonstrated positive results while confirming the validity of Xspray’s patented formulation technology The results will be helpful in designing of […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
